CGEM vs. XNCR, BDTX, MGNX, IPHA, SPPI, CRSP, KRYS, IBRX, IMVT, and SWTX
Should you be buying Cullinan Therapeutics stock or one of its competitors? The main competitors of Cullinan Therapeutics include Xencor (XNCR), Black Diamond Therapeutics (BDTX), MacroGenics (MGNX), Innate Pharma (IPHA), Spectrum Pharmaceuticals (SPPI), CRISPR Therapeutics (CRSP), Krystal Biotech (KRYS), ImmunityBio (IBRX), Immunovant (IMVT), and SpringWorks Therapeutics (SWTX). These companies are all part of the "medical" sector.
Cullinan Therapeutics (NASDAQ:CGEM) and Xencor (NASDAQ:XNCR) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their profitability, dividends, community ranking, analyst recommendations, earnings, risk, valuation, institutional ownership and media sentiment.
In the previous week, Cullinan Therapeutics had 1 more articles in the media than Xencor. MarketBeat recorded 6 mentions for Cullinan Therapeutics and 5 mentions for Xencor. Xencor's average media sentiment score of 1.55 beat Cullinan Therapeutics' score of 0.52 indicating that Xencor is being referred to more favorably in the news media.
Xencor has higher revenue and earnings than Cullinan Therapeutics. Xencor is trading at a lower price-to-earnings ratio than Cullinan Therapeutics, indicating that it is currently the more affordable of the two stocks.
86.3% of Cullinan Therapeutics shares are held by institutional investors. 6.1% of Cullinan Therapeutics shares are held by company insiders. Comparatively, 5.2% of Xencor shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Cullinan Therapeutics has a net margin of 0.00% compared to Xencor's net margin of -82.23%. Xencor's return on equity of -20.29% beat Cullinan Therapeutics' return on equity.
Cullinan Therapeutics has a beta of -0.01, suggesting that its share price is 101% less volatile than the S&P 500. Comparatively, Xencor has a beta of 0.77, suggesting that its share price is 23% less volatile than the S&P 500.
Cullinan Therapeutics presently has a consensus target price of $32.00, suggesting a potential upside of 35.48%. Xencor has a consensus target price of $35.43, suggesting a potential upside of 47.43%. Given Xencor's higher probable upside, analysts clearly believe Xencor is more favorable than Cullinan Therapeutics.
Xencor received 457 more outperform votes than Cullinan Therapeutics when rated by MarketBeat users. However, 79.55% of users gave Cullinan Therapeutics an outperform vote while only 72.89% of users gave Xencor an outperform vote.
Summary
Cullinan Therapeutics and Xencor tied by winning 9 of the 18 factors compared between the two stocks.
Get Cullinan Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for CGEM and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CGEM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Cullinan Therapeutics Competitors List
Related Companies and Tools
